NDA 021752/S-063

SUPPLEMENT APPROVAL

Gilead Sciences Inc
Attention: Helen Lam
Manager, Regulatory CMC
333 Lakeside Drive
Foster City, CA 94404

Dear Ms. Lam:

Please refer to your Supplemental New Drug Application (sNDA) dated and received April 14, 2023, and your amendment, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Truvada (emtricitabine/ tenofovir disoproxil fumarate) Tablets, 200 mg/300 mg, 100 mg/150 mg, 133 mg/200 mg, 167 mg/250 mg.

This "Changes Being Effected" supplemental new drug application provides for update to the USPI (Section 16, How Supplied/Storage and Handling) and the medication guide, to add a statement to reflect that once the bottle is opened, Truvada tablets are good for up to six weeks, as requested by FDA in the labeling request letter dated 21 March 2023

APPROVAL & LABELING

We have completed our review of this supplemental application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm. Content of labeling must be identical to the enclosed labeling (text for the prescribing information, and Medication Guide) with the addition of any labeling changes in pending "Changes Being Effected" (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eLIST may be found in the guidance for industry titled *SPL Standard for Content of Labeling Technical Qs and As* at http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf.

Information on submitting SPL files using eLIST may be found in the guidance for industry titled *SPL Standard for Content of Labeling Technical Qs and As* at http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf.

The SPL will be accessible via publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that include labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes, and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Omolara Oyinlola-Adeyemi, Regulatory Business Process Manager, at (240) 402 - 3842.

Sincerely,

{See appended electronic signature page}

David Lewis, Ph.D
Chief, Branch II
Division of Post-Marketing Activities I
Office of Lifecycle Drug Products
Office of Pharmaceutical Quality
Center for Drug Evaluation and Research

Enclosures:
Content of Labeling
Medication Guide

David Lewis

Digitally signed by David Lewis
Date: 10/11/2023 09:02:12AM
GUID: 508da72000029f287fa31e664741b577